MiMedx Group (MDXG) Stock Forecast, Price Target & Predictions
MDXG Stock Forecast
MiMedx Group stock forecast is as follows: an average price target of $11.75 (represents a 27.16% upside from MDXG’s last price of $9.24) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
MDXG Price Target
The average price target for MiMedx Group (MDXG) is $11.75 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $16.00 to $8.00. This represents a potential 27.16% upside from MDXG's last price of $9.24.
MDXG Analyst Ratings
According to 2 Wall Street analysts, MiMedx Group's rating consensus is 'Buy'. The analyst rating breakdown for MDXG stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
MiMedx Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | Anthony Petrone | Mizuho Securities | $16.00 | $9.09 | 76.11% | 73.16% |
| Jul 02, 2024 | Ross Osborn | Cantor Fitzgerald | $11.00 | $6.70 | 64.18% | 19.05% |
| Apr 29, 2024 | Brooks O'Neil | Lake Street | $12.00 | $6.26 | 91.54% | 29.87% |
| Sep 07, 2022 | - | H.C. Wainwright | $8.00 | $3.42 | 133.92% | -13.42% |
The latest MiMedx Group stock forecast, released on Nov 15, 2024 by Anthony Petrone from Mizuho Securities, set a price target of $16.00, which represents a 76.11% increase from the stock price at the time of the forecast ($9.09), and a 73.16% increase from MDXG last price ($9.24).
MiMedx Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $16.00 | $16.00 | $13.00 |
| Last Closing Price | $9.24 | $9.24 | $9.24 |
| Upside/Downside | 73.16% | 73.16% | 40.69% |
In the current month, the average price target of MiMedx Group stock is $16.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 73.16% increase as opposed to MiMedx Group's last price of $9.24. This month's average price target is down 0.00% compared to last quarter, and up 23.08% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 01, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Jul 02, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
MiMedx Group's last stock rating was published by Craig-Hallum on Aug 01, 2024. The company gave MDXG a "Buy" rating, the same as its previous rate.
MiMedx Group Financial Forecast
MiMedx Group Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $86.83M | $81.71M | $66.88M | $71.68M | $74.38M | $67.69M | $66.88M | $58.89M | $67.41M | $63.07M | $68.17M | $59.97M | $68.55M | $76.40M | $88.86M | $67.44M | $66.56M | $72.61M | $53.37M | $40.77M | $19.56M | $11.56M |
| Avg Forecast | $103.07M | $95.70M | $93.63M | $86.57M | $89.40M | $82.64M | $89.01M | $79.32M | $85.12M | $76.87M | $74.84M | $64.32M | $74.54M | $66.73M | $65.07M | $54.10M | $63.69M | $60.26M | $58.77M | $59.90M | $62.00M | $121.97M | $117.89M | $105.92M | $101.36M | $72.61M | $66.71M | $30.58M | $39.12M | $5.78M |
| High Forecast | $104.33M | $96.87M | $94.78M | $88.00M | $90.49M | $82.95M | $89.01M | $79.32M | $88.11M | $76.91M | $75.75M | $65.10M | $75.46M | $66.73M | $65.07M | $54.10M | $63.69M | $60.26M | $58.77M | $59.90M | $62.00M | $121.97M | $117.89M | $105.92M | $101.36M | $87.13M | $80.06M | $36.69M | $46.94M | $6.94M |
| Low Forecast | $101.19M | $93.96M | $91.93M | $84.20M | $87.77M | $82.33M | $89.01M | $79.32M | $82.55M | $76.83M | $73.48M | $63.15M | $73.19M | $66.73M | $65.07M | $54.10M | $63.69M | $60.26M | $58.77M | $59.90M | $62.00M | $121.97M | $117.89M | $105.92M | $101.36M | $58.09M | $53.37M | $24.46M | $31.30M | $4.62M |
| # Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 13 | 13 | 13 | 13 | 15 | 7 | 16 | 18 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | 1.02% | 1.06% | 0.89% | 1.11% | 1.00% | 1.01% | 1.03% | 1.09% | 1.06% | 1.05% | 1.16% | 1.00% | 1.11% | 0.63% | 0.75% | 0.64% | 0.66% | 1.00% | 0.80% | 1.33% | 0.50% | 2.00% |
MiMedx Group's average Quarter revenue forecast for Mar 24 based on 2 analysts is $79.32M, with a low forecast of $79.32M, and a high forecast of $79.32M. MDXG's average Quarter revenue forecast represents a -8.65% decrease compared to the company's last Quarter revenue of $86.83M (Dec 23).
MiMedx Group EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 13 | 13 | 13 | 13 | 15 | 7 | 16 | 18 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | $15.49M | $11.86M | $2.79M | $-2.48M | $2.05M | $-6.93M | $-8.61M | $-8.27M | $4.43M | $41.00K | $1.11M | $-5.45M | $-14.55M | $-5.42M | $13.98M | $-15.26M | $-11.30M | $7.51M | $2.96M | $4.82M | $-396.55K | $134.46K |
| Avg Forecast | $-3.03M | $-2.81M | $-2.75M | $-2.54M | $-2.62M | $-2.43M | $-2.61M | $-10.35M | $-2.50M | $-2.26M | $-2.20M | $-9.41M | $10.23M | $-1.93M | $-1.89M | $-7.44M | $-1.85M | $-1.75M | $-1.70M | $-7.49M | $-1.80M | $-3.54M | $-3.42M | $-3.07M | $-2.94M | $7.51M | $3.55M | $3.21M | $-535.35K | $147.90K |
| High Forecast | $-2.97M | $-2.76M | $-2.70M | $-2.47M | $-2.58M | $-2.42M | $-2.61M | $-8.28M | $-2.42M | $-2.26M | $-2.16M | $-7.53M | $12.27M | $-1.93M | $-1.89M | $-5.95M | $-1.85M | $-1.75M | $-1.70M | $-5.99M | $-1.80M | $-3.54M | $-3.42M | $-3.07M | $-2.94M | $9.01M | $4.26M | $3.86M | $-428.28K | $177.48K |
| Low Forecast | $-3.06M | $-2.84M | $-2.78M | $-2.58M | $-2.66M | $-2.44M | $-2.61M | $-12.43M | $-2.59M | $-2.26M | $-2.22M | $-11.30M | $8.18M | $-1.93M | $-1.89M | $-8.93M | $-1.85M | $-1.75M | $-1.70M | $-8.99M | $-1.80M | $-3.54M | $-3.42M | $-3.07M | $-2.94M | $6.01M | $2.84M | $2.57M | $-642.41K | $118.32K |
| Surprise % | - | - | - | - | - | - | - | - | -6.20% | -5.25% | -1.27% | 0.26% | 0.20% | 3.58% | 4.56% | 1.11% | -2.40% | -0.02% | -0.65% | 0.73% | 8.09% | 1.53% | -4.09% | 4.97% | 3.85% | 1.00% | 0.83% | 1.50% | 0.74% | 0.91% |
2 analysts predict MDXG's average Quarter EBITDA for Mar 24 to be $-10.35M, with a high of $-8.28M and a low of $-12.43M. This is -166.85% lower than MiMedx Group's previous annual EBITDA (Dec 23) of $15.49M.
MiMedx Group Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 13 | 13 | 13 | 13 | 15 | 7 | 16 | 18 | 17 |
| Net Income | - | - | - | - | - | - | - | - | $51.29M | $6.76M | $-10.87M | $-4.98M | $-415.00K | $-8.43M | $-10.87M | $-10.49M | $2.21M | $-2.34M | $-1.78M | $-8.38M | $-16.58M | $-7.48M | $12.38M | $-17.21M | $-13.27M | $4.33M | $1.20M | $4.09M | $-922.07K | $-1.62M |
| Avg Forecast | $15.33M | $12.36M | $11.38M | $8.90M | $10.68M | $6.53M | $11.13M | $-13.14M | $10.68M | $6.83M | $-2.97M | $-11.94M | $5.12M | $-11.54M | $-8.44M | $-9.44M | $-4.96M | $-11.91M | $-10.92M | $-11.51M | - | $28.29M | $22.33M | $20.85M | $19.36M | $4.33M | $1.44M | $2.72M | $-1.24M | $-1.78M |
| High Forecast | $15.57M | $12.56M | $11.56M | $9.04M | $10.85M | $6.68M | $11.30M | $-10.51M | $10.85M | $6.90M | $-2.90M | $-9.55M | $6.14M | $-11.54M | $-8.44M | $-7.55M | $-4.96M | $-11.91M | $-10.92M | $-9.21M | - | $28.29M | $22.33M | $20.85M | $19.36M | $5.19M | $1.72M | $3.27M | $-995.84K | $-1.43M |
| Low Forecast | $14.97M | $12.07M | $11.11M | $8.69M | $10.43M | $6.38M | $10.86M | $-15.76M | $9.35M | $6.75M | $-3.01M | $-14.33M | $4.09M | $-11.54M | $-8.44M | $-11.33M | $-4.96M | $-11.91M | $-10.92M | $-13.82M | - | $28.29M | $22.33M | $20.85M | $19.36M | $3.46M | $1.15M | $2.18M | $-1.49M | $-2.14M |
| Surprise % | - | - | - | - | - | - | - | - | 4.80% | 0.99% | 3.66% | 0.42% | -0.08% | 0.73% | 1.29% | 1.11% | -0.45% | 0.20% | 0.16% | 0.73% | - | -0.26% | 0.55% | -0.83% | -0.69% | 1.00% | 0.83% | 1.50% | 0.74% | 0.91% |
MiMedx Group's average Quarter net income forecast for Mar 24 is $-13.14M, with a range of $-15.76M to $-10.51M. MDXG's average Quarter net income forecast represents a -125.61% decrease compared to the company's last Quarter net income of $51.29M (Dec 23).
MiMedx Group SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 13 | 13 | 13 | 13 | 15 | 7 | 16 | 18 | 17 |
| SG&A | - | - | - | - | - | - | - | - | $54.35M | $52.57M | $51.92M | $52.28M | $49.95M | $53.48M | $55.79M | $49.57M | $53.07M | $46.29M | $53.60M | $45.40M | $48.71M | $45.44M | $51.26M | $50.64M | $50.86M | $52.95M | $40.65M | $29.31M | $15.85M | $8.37M |
| Avg Forecast | $74.10M | $68.81M | $67.32M | $62.24M | $64.28M | $59.42M | $63.99M | $62.08M | $61.20M | $55.27M | $53.81M | $56.44M | $53.60M | $47.98M | $46.78M | $44.61M | $45.79M | $43.33M | $42.25M | $43.07M | $44.58M | $87.70M | $84.76M | $76.15M | $72.87M | $52.95M | $48.78M | $19.54M | $21.40M | $4.16M |
| High Forecast | $75.01M | $69.65M | $68.14M | $63.27M | $65.06M | $59.64M | $63.99M | $74.49M | $63.35M | $55.30M | $54.46M | $67.72M | $54.25M | $47.98M | $46.78M | $53.54M | $45.79M | $43.33M | $42.25M | $43.07M | $44.58M | $87.70M | $84.76M | $76.15M | $72.87M | $63.54M | $58.53M | $23.45M | $25.68M | $4.99M |
| Low Forecast | $72.75M | $67.55M | $66.09M | $60.54M | $63.11M | $59.19M | $63.99M | $49.66M | $59.35M | $55.24M | $52.83M | $45.15M | $52.62M | $47.98M | $46.78M | $35.69M | $45.79M | $43.33M | $42.25M | $43.07M | $44.58M | $87.70M | $84.76M | $76.15M | $72.87M | $42.36M | $39.02M | $15.63M | $17.12M | $3.32M |
| Surprise % | - | - | - | - | - | - | - | - | 0.89% | 0.95% | 0.97% | 0.93% | 0.93% | 1.11% | 1.19% | 1.11% | 1.16% | 1.07% | 1.27% | 1.05% | 1.09% | 0.52% | 0.60% | 0.66% | 0.70% | 1.00% | 0.83% | 1.50% | 0.74% | 2.01% |
MiMedx Group's average Quarter SG&A projection for Mar 24 is $62.08M, based on 2 Wall Street analysts, with a range of $49.66M to $74.49M. The forecast indicates a 14.22% rise compared to MDXG last annual SG&A of $54.35M (Dec 23).
MiMedx Group EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 13 | 13 | 13 | 13 | 15 | 7 | 16 | 18 | 17 |
| EPS | - | - | - | - | - | - | - | - | - | $0.06 | $-0.09 | $-0.04 | $-0.00 | $-0.07 | $-0.10 | $-0.09 | $0.02 | $-0.02 | $-0.02 | $-0.08 | $-0.15 | $-0.07 | $0.12 | $-0.16 | $-0.12 | $0.04 | $0.01 | $0.04 | $-0.01 | $-0.02 |
| Avg Forecast | $0.10 | $0.08 | $0.08 | $0.06 | $0.07 | $0.04 | $0.07 | $0.04 | $0.07 | $0.05 | $-0.02 | $-0.09 | $-0.04 | $-0.08 | $-0.06 | $-0.10 | $-0.03 | $-0.08 | $-0.07 | $-0.19 | - | $0.19 | $0.15 | $0.14 | $0.13 | $0.07 | $0.06 | $0.02 | $-0.03 | $-0.01 |
| High Forecast | $0.10 | $0.08 | $0.08 | $0.06 | $0.07 | $0.04 | $0.08 | $0.05 | $0.07 | $0.05 | $-0.02 | $-0.08 | $-0.04 | $-0.08 | $-0.06 | $-0.10 | $-0.03 | $-0.08 | $-0.07 | $-0.19 | - | $0.19 | $0.15 | $0.14 | $0.13 | $0.08 | $0.07 | $0.02 | $-0.02 | $-0.01 |
| Low Forecast | $0.10 | $0.08 | $0.07 | $0.06 | $0.07 | $0.04 | $0.07 | $0.04 | $0.06 | $0.05 | $-0.02 | $-0.09 | $-0.04 | $-0.08 | $-0.06 | $-0.10 | $-0.03 | $-0.08 | $-0.07 | $-0.19 | - | $0.19 | $0.15 | $0.14 | $0.13 | $0.06 | $0.05 | $0.02 | $-0.03 | $-0.01 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 1.23% | 4.69% | 0.50% | 0.09% | 0.96% | 1.70% | 0.94% | -0.60% | 0.26% | 0.22% | 0.40% | - | -0.37% | 0.80% | -1.14% | -0.92% | 0.57% | 0.17% | 2.00% | 0.29% | 1.74% |
According to 2 Wall Street analysts, MiMedx Group's projected average Quarter EPS for Mar 24 is $0.04, with a low estimate of $0.04 and a high estimate of $0.05. This represents a 14900.00% increase compared to MDXG previous annual EPS of - (Dec 23).
MiMedx Group Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.28 | $15.00 | 1071.88% | Buy |
| NGM | NGM Biopharmaceuticals | $1.54 | $16.50 | 971.43% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $2.99 | $21.86 | 631.10% | Buy |
| HOWL | Werewolf Therapeutics | $1.67 | $12.00 | 618.56% | Buy |
| INZY | Inozyme Pharma | $2.81 | $14.67 | 422.06% | Buy |
| CCCC | C4 Therapeutics | $4.15 | $13.50 | 225.30% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.52 | $38.80 | 186.98% | Buy |
| GPCR | Structure Therapeutics | $32.78 | $92.40 | 181.88% | Buy |
| STOK | Stoke Therapeutics | $11.61 | $30.60 | 163.57% | Buy |
| CGEM | Cullinan Oncology | $13.10 | $31.50 | 140.46% | Buy |
| MLYS | Mineralys Therapeutics | $12.86 | $30.00 | 133.28% | Buy |
| ERAS | Erasca | $2.79 | $6.50 | 132.97% | Buy |
| SNDX | Syndax Pharmaceuticals | $15.77 | $34.30 | 117.50% | Buy |
| CVKD | Cadrenal Therapeutics | $15.13 | $32.00 | 111.50% | Buy |
| KROS | Keros Therapeutics | $53.62 | $102.60 | 91.35% | Buy |
| DSGN | Design Therapeutics | $5.48 | $9.67 | 76.46% | Buy |
| EWTX | Edgewise Therapeutics | $31.51 | $45.00 | 42.81% | Buy |
| CNTA | Centessa Pharmaceuticals | $16.83 | $23.25 | 38.15% | Buy |
| PTGX | Protagonist Therapeutics | $38.65 | $50.00 | 29.37% | Buy |
| MDXG | MiMedx Group | $9.24 | $11.75 | 27.16% | Buy |
| IKNA | Ikena Oncology | $1.68 | $1.33 | -20.83% | Buy |